Neuroblastoma refers to a malignant cancer disease that affects the nerve tissue in different parts of the body, primarily the nerve tissue of the spinal cord, adrenal glands, chest and neck. However, the disease is believed to begin from the adrenal glands and spread to the other nerve tissues. In most cases, neuroblastoma sets in the early childhood, especially in children below the age of 5 years, and persists into adulthood. In rare occasions, malignant cancer cells form during the fetal development stages of the fetus, long before the child is born, as it has been identified in ultrasound results.
In practice, neuroblastoma presents some difficulties in both management and diagnosis because this cancer spreads rapidly and this explains why diagnosis is usually done when the disease has already metastasized to the bones, lymph nodes, skin and the liver.
Table of Contents
1. Introduction to Neuroblastoma
2. Prevalence and Epidemiology
3. Signs and Symptoms
4. Risk Factors
5. Diagnosis
6. Treatment Modalities
6.1 Surgery
6.2 Radiotherapy
6.3 Chemotherapy
6.4 Stem Cell Therapy and Monoclonal Antibody Treatment
7. Ongoing Research and Clinical Trials
8. Conclusion
Research Objectives and Themes
The primary objective of this paper is to provide a comprehensive overview of neuroblastoma, a malignant cancer affecting the nerve tissue in children. The work examines the clinical presentation, established risk factors, current diagnostic methodologies, and the standard as well as emerging treatment modalities used to manage this disease.
- Pathophysiology and clinical manifestation of neuroblastoma
- Epidemiological data and risk factor identification
- Diagnostic procedures including biomarker analysis and nuclear scanning
- Standard treatments (Surgery, Radiotherapy, Chemotherapy)
- Emerging therapeutic strategies (Stem cell support and Monoclonal antibodies)
Excerpt from the Book
Diagnosis of Neuroblastoma
On the other hand, diagnosis of neuroblastoma encompasses numerous tests and investigations ranging from blood tests, biopsy and bone marrow tests to scans. Ideally, tests are usually done to ascertain whether a child has neuroblastoma or not. They also help in determining the spread of the cancer because neuroblastomas exhibit rapid metastasis. On the other hand, nuclear medicine scans are done to identify the exact location of the tumor, in order to decide on the most appropriate treatment option. Some of the most reliable tests for diagnosing neuroblastoma are Vanillylmandelic acid (VMA) test and Homovanillic acid (HVA) test, in which urine samples are collected and analyzed for the presence of homovanillic acid and vanillylmandelic acid levels. These tests are essential in the diagnosis of neuroblastoma because; 9 of 10 children with neuroblastoma show increased levels of these two metabolites in their urine; thus, it helps in confirming diagnosis.
In addition, VMA and HMA tests play a significant role in monitoring the progress of treatment by observing the decrease of these compounds in urine samples of neuroblastoma patients. Other reliable diagnostic methods are biopsies and metaiodobenzyl guanine (MIBG) scans. In biopsy diagnosis, tissue lesions are collected during an operation for microscopic and histological investigations. On the other hand, MIBG scans employ the principle of radiation scanning to determine the exact location of neuroblastoma tumors. In this diagnostic approach, metaiodobenzyl guanine, a radioactive substance is injected into the patient’s blood circulation, whereby it is taken up by tumor cells; thus allowing easy location. Therefore, radiation scanning determines the levels of radioactive iodine to identify the location of the tumor.
Summary of Chapters
Introduction to Neuroblastoma: Defines the disease as a malignant cancer originating from nerve tissue, particularly in the adrenal glands, which primarily affects early childhood.
Prevalence and Epidemiology: Provides statistics on the incidence rates of neuroblastoma across various regions, highlighting its status as one of the most common childhood cancers.
Signs and Symptoms: Details the clinical indicators, ranging from physical lumps and abdominal swelling to systemic symptoms like blood pressure fluctuations and bone pain.
Risk Factors: Explores the influence of age and genetic predisposition, noting that while family history is a factor, most cases do not show clear inheritance patterns.
Diagnosis: Explains the necessity of metabolic urine tests, biopsy procedures, and advanced imaging techniques like MIBG scans for staging the disease.
Treatment Modalities: Evaluates the efficacy of conventional treatments such as surgery, radiotherapy, and chemotherapy, alongside advanced support like stem cell therapy.
Ongoing Research and Clinical Trials: Discusses promising new avenues of treatment, including monoclonal antibodies like anti-GD2 and studies on specific gene expression inhibitors.
Conclusion: Summarizes the current understanding of the disease and emphasizes the critical importance of ongoing clinical research for improved patient outcomes.
Keywords
Neuroblastoma, Childhood Cancer, Adrenal Gland, Metastasis, VMA, HVA, MIBG Scans, Radiotherapy, Chemotherapy, Stem Cell Therapy, Anti-GD2, Oncology, Pediatric Medicine, MYCN gene, Tumor Diagnosis
Frequently Asked Questions
What is the fundamental subject of this document?
This document provides an overview of neuroblastoma, a malignant pediatric cancer affecting nerve tissue, covering its characteristics, causes, and medical management.
What are the central thematic fields covered in this paper?
The text focuses on the epidemiology, clinical symptoms, diagnostic methodologies, and the evolution of treatment strategies for neuroblastoma.
What is the primary objective of this research summary?
The goal is to synthesize existing knowledge regarding neuroblastoma diagnosis and treatment to highlight how medical science addresses this aggressive disease.
Which scientific methods are discussed for diagnosis?
Common diagnostic methods discussed include VMA and HVA urine metabolite testing, tissue biopsies, and nuclear medicine scans such as MIBG.
What primary treatment modalities are examined?
The document reviews surgery for localized tumors, radiotherapy for metastasized cases, and systemic chemotherapy, alongside innovative stem cell support.
Which keywords best characterize this work?
The work is defined by terms such as childhood cancer, neuroblastoma, metastasis, chemotherapy, monoclonal antibodies, and genetic biomarkers.
How is the role of surgery defined in the context of localized tumors?
Surgery is presented as the primary option for localized tumors in the early stages, aimed at removing the mass before the disease metastasizes to bones or lymph nodes.
What is the significance of the Nifurtimox study mentioned in the text?
The Nifurtimox study is highlighted as a current research effort investigating its potential efficacy when combined with other drugs for relapsed or refractory neuroblastoma.
- Citation du texte
- Patrick Kimuyu (Auteur), 2018, Pathophysiology of Neuroblastoma, Munich, GRIN Verlag, https://www.grin.com/document/388315
